This website uses cookies
Read our Privacy policy and Terms of use for more information.
Long Form Content
Aug 25, 2026
•
3 min read
🧬 FDA grants Capricor Therapeutics three-month extension to review (deramiocel) Ph3 data for Duchenne muscular dystrophy upper limb indication, Johnson & Johnson's Imaavy (nipocalimab) gains FDA label expansion for warm autoimmune hemolytic anemia backed by Ph2/3 data, Eli Lilly launches oral obesity pill Foundayo in UK, challenging Novo Nordisk's head-start Wegovy pill
Aug 24, 2026
🧬 Roche, Hanmi Pharm partner on weight loss drug HM17321, $190M upfront, up to $2.3B deal, Lundbeck reports 16% sales growth in H1 2026, driven by Vyepti and Rexulti gains, Spruce Biosciences advances toward Q4 FDA filing for ultra-rare Sanfilippo syndrome drug after successful manufacturing talks
Aug 21, 2026
2 min read
🧬Roche invests $750M to double Oregon Genentech facility, adding fill-finish manufacturing capacity by 2031, Werewolf Therapeutics, Ambros Therapeutics merge in $150M deal targeting rare CRPS-1 pain disorder, Aurinia Pharmaceuticals settles with Teva Pharmaceuticals, protecting Lupkynis from generics until December 2036
Aug 20, 2026
🧬 Ultragenyx wins first gene therapy FDA approval for Genglycos (DTX401) targeting glycogen storage disease type Ia via Ph3, Kynexis raises €97M ($113M) Series A, advancing cognitive impairment schizophrenia drug to registrational development, Regeneron wins FDA approval for Pasatru (garetosmab) targeting Activin A in fibrodysplasia ossificans progressiva based on Ph3 data
Aug 19, 2026
🧬 Merck & Co., Moderna's intismeran autogene (mRNA-4157) plus Keytruda (pembrolizumab) reduces recurrence risk in Ph3 melanoma trial, Trump nominates White House aide Heidi Overton as new FDA commissioner, CSL shares surge 17% on immunoglobulin demand recovery and stronger-than-expected $15.8B revenue
Aug 18, 2026
🧬 Amylyx Pharmaceuticals eyes FDA filing for (avexitide) after Ph3 win in post-bariatric hypoglycemia, BioMarin Pharmaceutical acquires Alesta Therapeutics for $275M to challenge AstraZeneca in rare bone disease market, Biokin Pharma's (iza-bren) EGFRxHER3 bispecific ADC meets Ph3 primary endpoint in EGFR-mutated nonsquamous non-small cell lung cancer
Aug 17, 2026
🧬 Vera Therapeutics' Trutakna shows kidney function stabilization in Ph3, rivaling Otsuka's Voyxact in immunoglobulin A nephropathy, Slate Medicines reverse merges with Fulcrum Therapeutics, raises $245M for migraine antibody trials on Nasdaq, AstraZeneca's Tagrisso (osimertinib) plus Orpathys (savolitinib) meets PFS and overall survival goals in Ph3 EGFR-mutated non-small-cell lung cancer trial
Aug 14, 2026
🧬 FDA grants Bristol Myers Squibb accelerated approval for Zenbexus (iberdomide), a CELMoD agent, for multiple myeloma, Vogenx raises $81.3M IPO, clinical-stage biopharma targeting metabolic serious diseases, Capricor Therapeutics soars after FDA greenlights amendment to DMD cell therapy approval application
Aug 13, 2026
🧬 PTC Therapeutics acquires Sangamo Therapeutics' Fabry gene therapy for $111M upfront, $100M milestones, Taiho Pharmaceutical, Cullinan Therapeutics' (zipalertinib) EGFR inhibitor meets Ph3 primary endpoint in first-line non-small cell lung cancer, Akeso's ivonescimab wins China Ph3-backed approval for first-line squamous non-small-cell lung cancer
Aug 12, 2026
🧬 BridgeBio's Attruby hits $222M quarterly sales, nearing blockbuster status as ATTR stabilizer-first market emerges, Definium Therapeutics' DT120 (LSD) succeeds in Ph3 trial for generalized anxiety disorder, InduPro raises $77M Series B, backed by Sanofi and Lilly, funding cancer pipeline advancement
Aug 11, 2026
🧬 Bristol Myers Squibb commits $2.3B to build Houston manufacturing campus, creating 2,500 jobs, Jazz Pharmaceuticals to acquire Actio Biosciences for up to $1.3B, expanding rare epilepsy pipeline, Vaderis Therapeutics raises $152M Series B to advance AKT-targeting HHT treatment
Aug 10, 2026
🧬 Novo Nordisk, Amazon Web Services partner on AI drug discovery, launch London innovation hub, Silence Therapeutics' (divesiran) hits primary endpoint in Ph2 trial targeting TMPRSS6 for polycythemia vera, AbCellera's (ABCL635) Ph2 data surpass rivals in NK3R-targeting therapy for menopause-related hot flashes
